These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22647638)

  • 1. Pulmonary cryptococcosis in a patient with Crohn's disease treated with prednisone, azathioprine and adalimumab: exposure to chicken manure as a source of contamination.
    Fraison JB; Guilpain P; Schiffmann A; Veyrac M; Le Moing V; Rispail P; Le Quellec A
    J Crohns Colitis; 2013 Feb; 7(1):e11-4. PubMed ID: 22647638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab.
    Desales AL; Mendez-Navarro J; Méndez-Tovar LJ; Ortiz-Olvera NX; Cullen G; Ocampo J; Lemus W; Tun AE; Mayoral-Zavala A; Dehesa-Violante M
    J Crohns Colitis; 2012 May; 6(4):483-7. PubMed ID: 22398055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crohn's-like disease in a patient with common variable immunodeficiency treated with azathioprine and adalimumab.
    Vázquez-Morón JM; Pallarés-Manrique H; Martín-Suárez IJ; Benítez-Rodríguez B; Ramos-Lora M
    Rev Esp Enferm Dig; 2013; 105(5):299-302. PubMed ID: 23971663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histoplasma epiglottitis in a patient with Crohn's disease maintained on infliximab, prednisone, and azathioprine.
    Abou Zahr A; Saad Aldin E; Yunyongying P
    Int J Infect Dis; 2013 Aug; 17(8):e650-2. PubMed ID: 23769453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
    Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
    J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.
    Matsumoto T; Motoya S; Watanabe K; Hisamatsu T; Nakase H; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    J Crohns Colitis; 2016 Nov; 10(11):1259-1266. PubMed ID: 27566367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cavitary pulmonary cryptococcosis with an Aspergillus fungus ball.
    Makino Y; Nishiyama O; Sano H; Iwanaga T; Higashimoto Y; Kume H; Tohda Y
    Intern Med; 2014; 53(23):2737-9. PubMed ID: 25447660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disseminated cryptococcosis in Crohn's disease: a case report.
    Chavapradit N; Angkasekwinai N
    BMC Infect Dis; 2018 Dec; 18(1):620. PubMed ID: 30514241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Severe lymphopenia in a patient with Crohn's disease].
    Monasterio C; Kreisel W; Hasselblatt P
    Internist (Berl); 2018 Aug; 59(8):857-860. PubMed ID: 29356833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature.
    Verma S; Kroeker KI; Fedorak RN
    BMC Gastroenterol; 2013 Apr; 13():59. PubMed ID: 23556424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
    Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G;
    J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond?
    Fiorino G; Danese S
    J Crohns Colitis; 2016 Nov; 10(11):1257-1258. PubMed ID: 27389085
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease.
    Casanova MJ; Chaparro M; Martínez S; Vicuña I; Gisbert JP
    J Crohns Colitis; 2012 Dec; 6(10):1034-7. PubMed ID: 22534313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vulval Crohn's disease: a clinical study of 22 patients.
    Laftah Z; Bailey C; Zaheri S; Setterfield J; Fuller LC; Lewis F
    J Crohns Colitis; 2015 Apr; 9(4):318-25. PubMed ID: 25687208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disseminated Cryptococcus neoformans infection and Crohn's disease in an immunocompetent patient.
    Sciaudone G; Pellino G; Guadagni I; Somma A; D'Armiento FP; Selvaggi F
    J Crohns Colitis; 2011 Feb; 5(1):60-3. PubMed ID: 21272807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
    Kiss LS; Szamosi T; Molnár T; Miheller P; Lakatos L; Vincze A; Palatka K; Bartha Z; Gasztonyi B; Salamon A; Horváth G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovász BD; Végh Z; Golovics PA; Szathmári M; Papp M; Lakatos PL
    Orv Hetil; 2011 Sep; 152(36):1433-42. PubMed ID: 21865144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.